AIM ImmunoTech commits $1.5 million to Ampligen drug substance batches in Sterling Pharma pact
In focus: AIM ImmunoTech (NYSE American: AIM) and a July 31, 2026, Proposal Agreement with contract manufacturer Sterling Pharma Solutions that commits approximately $1.5 million over 12 months to produce fresh batches…